Evidence map›Paper›PMID 34546657›Full record

ArticleJournal of the International AIDS Society2021

Naomi: a new modelling tool for estimating HIV epidemic indicators at the district level in sub-Saharan Africa.

Jeffrey W Eaton, Laura Dwyer-Lindgren, Steve Gutreuter, Megan O'Driscoll, Oliver Stevens, Sumali Bajaj, Rob Ashton, Alexandra Hill, Emma Russell, Rachel Esra and 26 more

Abstract read
In one paragraph

Article in Journal of the International AIDS Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Updated Data and Methods for the 2023 UNAIDS HIV Estimates.Journal of acquired immune deficiency syndromes (1999) · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Jeffrey W EatonMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.ORCID 0000-0001-7728-728X
Laura Dwyer-LindgrenInstituted for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA.
Steve GutreuterDivision of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Megan O'DriscollMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
Oliver StevensMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.ORCID 0000-0001-6842-9434
Sumali BajajMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
Rob AshtonMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
Alexandra HillMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
Emma RussellMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
Rachel EsraMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
Nicolas DolanMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
Yusuf O AnifowosheMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
Mark WoodbridgeMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
Ian FellowsFellows Statistics, San Diego, California, USA.
Robert GlaubiusAvenir Health, Glastonbury, Connecticut, USA.ORCID 0000-0002-4936-0264
Emily HaeuserInstituted for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA.
Taylor OkonekDepartment of Biostatistics, University of Washington, Seattle, Washington, USA.
John StoverAvenir Health, Glastonbury, Connecticut, USA.ORCID 0000-0001-7236-1989
Matthew L ThomasMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
Jon WakefieldDepartment of Biostatistics, University of Washington, Seattle, Washington, USA.
Timothy M WolockMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.ORCID 0000-0001-5898-1014
Jonathan BerryFjelltopp, Padiham, UK.
Tomasz SabalaFjelltopp, Padiham, UK.
Nathan HeardUS Department of State, Washington, District of Columbia, USA.
Stephen DelgadoICAP, Mailman School of Public Health, Columbia University, New York, New York, USA.
Andreas JahnDepartment of HIV & AIDS, Ministry of Health, Lilongwe, Malawi.
Thokozani KaluaDepartment of HIV & AIDS, Ministry of Health, Lilongwe, Malawi.
Tiwonge ChimpanduleDepartment of HIV & AIDS, Ministry of Health, Lilongwe, Malawi.
Andrew AuldDivision of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Lilongwe, Malawi.
Evelyn KimDivision of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Lilongwe, Malawi.
Danielle PayneDivision of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Lilongwe, Malawi.
Leigh F JohnsonCentre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-2717-011X
Richard G FitzJohnMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
Ian WanyekiStrategic Information Department, Joint United Nations Program on HIV/AIDS (UNAIDS), Geneva, Switzerland.
Mary I MahyStrategic Information Department, Joint United Nations Program on HIV/AIDS (UNAIDS), Geneva, Switzerland.ORCID 0000-0001-6023-3023
Ray W ShiraishiDivision of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Funding

STATISTICAL ISSUES IN AIDS RESEARCHR37AI029168 · NIAID · UNIVERSITY OF WASHINGTON · PI JAMES P HUGHES · 1999 to 2026
$9.8M
STATISTICAL ISSUES IN AIDS RESEARCHR01AI029168 · NIAID · UNIVERSITY OF WASHINGTON · PI HUGHES, JAMES P · 1989 to 2018
$5.3M
Statistical Models for Estimating and Projecting HIV/AIDS EpidemicsR01AI136664 · NIAID · PENNSYLVANIA STATE UNIVERSITY, THE · PI BAO, LE · 2017 to 2021
$3.6M
Quantifying Spatial Representativeness and Uncertainty in Antenatal Care Sentinel Surveillance for HIV in Sub-Saharan Africa.R03AI125001 · NIAID · IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE · PI EATON, JEFFREY WILLIAM · 2017 to 2018
$105k
Medical Research Council MR/R015600/1NIAID NIH HHS R01 AI029168NIAID NIH HHS R01 AI136664NIAID NIH HHS R03 AI125001NIAID NIH HHS R37 AI029168
6 · The paper itself

Abstract

introductionHIV planning requires granular estimates for the number of people living with HIV (PLHIV), antiretroviral treatment (ART) coverage and unmet need, and new HIV infections by district, or equivalent subnational administrative level. We developed a Bayesian small-area estimation model, called Naomi, to estimate these quantities stratified by subnational administrative units, sex, and five-year age groups.

methodsSmall-area regressions for HIV prevalence, ART coverage and HIV incidence were jointly calibrated using subnational household survey data on all three indicators, routine antenatal service delivery data on HIV prevalence and ART coverage among pregnant women, and service delivery data on the number of PLHIV receiving ART. Incidence was modelled by district-level HIV prevalence and ART coverage. Model outputs of counts and rates for each indicator were aggregated to multiple geographic and demographic stratifications of interest. The model was estimated in an empirical Bayes framework, furnishing probabilistic uncertainty ranges for all output indicators. Example results were presented using data from Malawi during 2016-2018.

resultsAdult HIV prevalence in September 2018 ranged from 3.2% to 17.1% across Malawi's districts and was higher in southern districts and in metropolitan areas. ART coverage was more homogenous, ranging from 75% to 82%. The largest number of PLHIV was among ages 35 to 39 for both women and men, while the most untreated PLHIV were among ages 25 to 29 for women and 30 to 34 for men. Relative uncertainty was larger for the untreated PLHIV than the number on ART or total PLHIV. Among clients receiving ART at facilities in Lilongwe city, an estimated 71% (95% CI, 61% to 79%) resided in Lilongwe city, 20% (14% to 27%) in Lilongwe district outside the metropolis, and 9% (6% to 12%) in neighbouring Dowa district. Thirty-eight percent (26% to 50%) of Lilongwe rural residents and 39% (27% to 50%) of Dowa residents received treatment at facilities in Lilongwe city.

conclusionsThe Naomi model synthesizes multiple subnational data sources to furnish estimates of key indicators for HIV programme planning, resource allocation, and target setting. Further model development to meet evolving HIV policy priorities and programme need should be accompanied by continued strengthening and understanding of routine health system data.

Indexed as

EpidemicsHIV InfectionsAdultAnti-Retroviral AgentsBayes TheoremFemaleHumansMalawiMalePregnancyPrevalenceAnti-Retroviral AgentsBayesian statisticsHIV estimatesjoint modellingroutine datasmall-area estimation

Identifiers

PMID34546657
PMCPMC8454682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.